ĐÁNH GIÁ HIỆU QUẢ TIÊM NỘI NHÃN RANIBIZUMAB (LUCENTIS) TRONG ĐIỀU TRỊ PHÙ HOÀNG ĐIỂM DO TẮC TĨNH MẠCH VÕNG MẠC

Abstract

Objective: To evaluate the efficacy of intravitreal Ranibizumab (Lucentis) injection in the treatment of macular edema secondary to retinal vein occlusion (RVO). Subjects and Methods: this was a prospective, interventional, uncontrolled study conducted on 51 eyes of 51 patients diagnosed with RVO-induced macular edema. All patients received three consecutive intravitreal injections of Ranibizumab (0.5 mg/0.05 ml), administered at 4-week intervals. The study assessed changes in visual acuity and central retinal thickness (CRT) following treatment. Results: the mean best-corrected visual acuity (BCVA) before treatment was 1.25 ± 0.72 logMAR, which significantly improved to 0.56 ± 0.41 logMAR at 12 weeks post-treatment. Among the participants, 86.3% experienced significant visual improvement (gain of ≥3 lines), 13.7% had moderate improvement, and no patient showed visual deterioration. The mean CRT decreased from 534.1 ± 169 µm to 260.6 ± 37 µm after three months, with an average reduction of 273.5 ± 156.8 µm. Notably, 41.2% of eyes achieved normalization of CRT (<250 µm). Conclusion: Intravitreal Ranibizumab injection is an effective and safe treatment for macular edema secondary to retinal vein occlusion, resulting in significant anatomical and functional improvement.